meta
|
COVID-19
Dynamic meta-analysis of evidences about drug efficacy and safety
586
adjuvant therapies
anticoagulant
anticoagulant, curative dose
anticoagulant, prophylactic dose
Bivalirudin
heparin at therapeutic dose
sulodexide
colchicine
face mask
febuxostat
hydrogen-oxygen nebulizer
hyperbaric oxygen
nintedanib
pulmonary rehabilitation
thalidomide
vitamin C
anti-inflammatoty and immuno-therapy
A EFFACER anticorps
acalabrutinib
anti-inflammatory therapies
IFX-1
mepolizumab
naproxen, ibuprofen
non-steroidal anti-inflammatory drugs
Celecoxib
Ibuprofen
Indomethacin
sodium aescinate
Apilimod
corticosteroids
ciclesonide
dexamethasone
Hydrocortisone
inhaled steroids
low-dose corticosteroids
methylprednisolone
imatinib
Immunostimulants drugs
anti-PD-1 antibody
CD24Fc
convalescent plasma treatment
immunoglobulin therapy
emapalumab
inactivated mycobacterium vaccine
interferon
interferon / TFF2
SNG001 inhaled interferon beta
Interleukin-2
neutralizing antibody
bamlanivimab (LY-CoV555)
casirivimab and imdevimab
rhG-CSF
Vitamin D
Immunosuppressants drugs
adalimumab
anakinra
anti-interleukin-6
clazakizumab
sarilumab
sarilumab azithromycin hydroxychloroquine
sarilumab high dose (400mg)
sarilumab low dose (200mg)
siltuximab
tocilizumab
baricitinib
baricitinib plus remdesivir
eculizumab
jakotinib
lenzilumab
ruxolitinib
tacrolimus
tetrandrine
leflunomide
pirfenidone
Polyinosinic-Polycytidylic Acid
sargramostim
thymosin
antiviral and associated therapy
ASC09/ritonavir
azithromycin
azvudine
baloxavir marboxil
carrimycin
chloroquine and derivatives
chloroquine
hydroxychloroquine
danoprevir / ritonavir
darunavir cobicistat
darunavir/cobicistat plus chloroquine
doxycycline
favipiravir
fluvoxamine
hydroxychloroquine plus macrolides
ivermectin
leronlimab
lopinavir / ritonavir plus ribavirin
lopinavir/ritonavir
lopinavir/ritonavir plus chloroquine
lopinavir/ritonavir plus interferon ß-1a
lopinavir/ritonavir, ribavirin and interferon beta-1b
meplazumab
nitazoxanide
oseltamivir
oseltamivir plus chloroquin
remdesivir
Renin-angiotensin-system-acting agents
angiotensin converting enzyme inhibitors (ACEIs)
angiotensin receptor blockers (ARBs)
angiotensin-(1-7)
discontinuation of ACEI/ARB
RAS blocker withdrawal
rhACE2
ribavirin
ritonavir
sofosbuvir and daclatasvir
tenofovir/emtricitabine
tenofovir/emtricitabine plus hydroxychloroquine
tranexamic acid
triazavirin
umifenovir (arbidol)
control
placebo
prone positioning
standard of care
honey
miscellaneous
5-alpha-reductase inhibitors
acetylcysteine
alpha lipoic acid
aviptadil
bevacizumab
bismuth
BLD-2660 (calpain inhibitor)
calcium channel blocker
camostat mesilate
continuous positive airway pressure (CPAP)
cytokine adsorption
diammonium glycyrrhizinate
dipyridamol
DPP-4 inhibitor
enoxaparin
famotidine
kinin-kallikrein inhibitors
levamisole
metformin
natural killer (NK) cells
nicotin
nitric oxide (gas Inhalation or releasing solution)
ozonated autohemotherapy
pamrevlumab
povidone-iodine
proton pump inhibitors (PPI)
proxalutamide
PUL-042 inhalation solution
radiotherapy
selinexor
statins
stem cells
tradipitant
tranilast
zinc
zinc plus hydroxychloroquine
vaccines
Ad26.COV2.S A EFFACER
BBV152
BCG vaccination
CureVac
DNA vaccine
bacTRL-Spike
Inactivated virus vaccine
Covaxin, Bharat Biotech, Indian Council of Medical Research
Sinopharm Beijing (BBIBP-CorV)
Sinopharm Wuhan
SinoVac Biotech
Non replicating viral vector
CanSino
ChAdOx1 nCoV-19 (AstraZeneca Oxford)
JNJ-78436735 AD26 (Jonson
Sputnik V (Gam-COVID-Vac)
protein subunit vaccine
Anhui Zhifei Longcom
NVX-CoV2373 (Novavax)
RNA vaccine
Moderna COVID-19 vaccine
tozinameran (Pfizer/BIONTECH)
SCB-2019
virus-like particles vaccine
Medicago
All
COVID-19
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 prophylaxis
infections other than COVID-19
preventing respiratory virus transmission